Results of MAIC study comparing pirtobrutinib ... - CLL Support
Results of MAIC study comparing pirtobrutinib vs venetoclax in CLL patients previously treated with a covalent BTK inhibitor
You need to be a member of this community to see this post.
Read more about...
7 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Adding Venetoclax to Obinutuzumab Prolongs Progression-Free Survival in Previously Untreated CLL
September 2019
In a phase III trial of patients with previously untreated CLL and...
Encouraging results from venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
response to a second venetoclax treatment, from a trial of 46 CLL patients who relapsed after their...
COVID-19 among fit patients with CLL treated with venetoclax-based combinations
COVID-19 in CLL patients receiving venetoclax-based combinations and CIT as first-line treatment...
Survey for CLL patients having taken Venetoclax or Acalabrutinib
first-line treatment of CLL/SLL
Acalabrutinib (Calquence) monotherapy for treatment of...
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
Title: COMBINED PIRTOBRUTINIB, VENETOCLAX, AND OBINUTUZUMAB INFIRST-LINE TREATMENT OF PATIENTS WITH...
Related Posts
- Duvelisib Dosing Modification Does Not Compromise Efficacy in Heavily Pretreated CLL/SLL
Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial - Phase I/II trial of IPH2201 checkpoint inhibitor in combination with ibrutinib opens for patients with relapsed or refractory CLL
New drug: MS-553 inhibitor for CLL/SLL who develop resistance to BTK inhibitors- Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
